AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00134199
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005549
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
Trial: NCT03272009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
Trial: NCT02546609
Drug: Leu-Met-Sil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-0200 low dose
Trial: NCT02546609
Drug: Leu-Met-Sil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-200 high dose
Trial: NCT04110054
Drug: Placebo to S-600918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT04363866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a pill that looks like the study drug but has no real medicine in it.
Trial: NCT00264628
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02198313
Drug: BIIX 1 XX - D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02198313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01216644
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Trial: NCT00963469
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet orally once daily in the morning for 4 weeks
Trial: NCT02546609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01719627
Drug: TVD 300/200 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVD 300/200 QD during 7 days
Trial: NCT03080324
Drug: Fentanyl ev
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl ev
Trial: NCT03080324
Drug: Placebo sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual
Trial: NCT03080324
Drug: Placebo ev
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02101281
Drug: rhNGF 20 µg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop for each eye, twice daily for 28 day
Trial: NCT02101281
Drug: rhNGF 4 µg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop each eye, twice daily for 28 day
Trial: NCT03450434
Drug: XC8 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
Trial: NCT03450434
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
Trial: NCT03160638
Drug: Azithromycin 250 mg
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
Trial: NCT00799552
Drug: RX-10045
RxNorm normalized name: BARRIER,SENSURA COLOPLAST #10045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX-10045 eye drop
Trial: NCT00799552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drop
Trial: NCT00002755
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002755
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002755
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002755
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002755
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00448669
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04287985
Drug: Dose-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit Dose Strength - 0.9%.
Trial: NCT01571804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to receive two identical placebo capsules 1 hr before surgery
Trial: NCT03762772
Drug: TAF/EVG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 combination vaginal insert (20mg TAF/16mg EVG)
Trial: NCT02638337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet identical to the ospemifene tablet without drug
Trial: NCT02988089
Drug: Clarithromycin susceptibility dependant strategy
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen.
Trial: NCT02988089
Drug: 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )
RxNorm normalized name: bismuth subcitrate, tetracycline and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Trial: NCT02988089
Drug: amoxicillin and clarithromycin or amoxicillin and furazolidone
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in the 6 antibiotics dependant group will use these intervention.
Trial: NCT02293265
Drug: Short Acting Beta Agonist (SABA)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
Trial: NCT02008981
Drug: Siwu Tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Trial: NCT05673746
Drug: treatment of physician choice, according to the standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
Trial: NCT00920972
Drug: Treatment Plan 1: Stratum 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
Trial: NCT00920972
Drug: Treatment Plan 2: Strata 2, 3, or 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -50 to -21: Hydroxyurea 30mg/kg PO q day... Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
Trial: NCT00920972
Drug: GVHD Regimen A: UCB Recipients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
Trial: NCT00920972
Drug: GVHD Regimen B: BM Recipients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
Trial: NCT00468273
Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
RxNorm normalized name: GLOBULIN,IMMUNE (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
Trial: NCT01154387
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
Trial: NCT01340066
Drug: UISH001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual dosing, 1 drop 3 times a day
Trial: NCT01340066
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual dosing,1 drop 3 times a day
Trial: NCT04187898
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.
Trial: NCT04481412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96% ethanol that will be applied once daily.
Trial: NCT01622439
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
Trial: NCT01622439
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Trial: NCT03284463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Trial: NCT01791244
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468389
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900-1000mg/m2 bid, days 1-14, every 3 weeks
Trial: NCT01468389
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
Trial: NCT01691079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo administered before exercise.
Trial: NCT00445315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04139434
Drug: LP-108
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
Trial: NCT03092726
Drug: ASP8062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
Trial: NCT03092726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
Trial: NCT02639975
Drug: PBF-677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily oral administration
Trial: NCT02639975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily oral administration
Trial: NCT03443661
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
Trial: NCT00603954
Drug: Conditioning regimen:TLI (8 Gy) + ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
Trial: NCT03191981
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Trial: NCT02117752
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches containing normal saline (Negative Control) will be applied to the skin.
Trial: NCT02520726
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched encapsulated placebo from 1-4 capsules daily
Trial: NCT02713126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
Trial: NCT00697502
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.
Trial: NCT03912831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT01460667
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
Trial: NCT01657604
Drug: Peginterferon α2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
Trial: NCT04335617
Drug: MMPF (Micronized purified Flavonoid-Fraction)
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
Trial: NCT03657030
Drug: CVN424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD / MAD
Trial: NCT03657030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04499755
Drug: Nucleo CMP Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleo CMP Forte twice daily for 6 weeks
Trial: NCT00738322
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for iv infusion, single dose
Trial: NCT00738322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl solution for iv infusion, single dose
Trial: NCT00391196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo plus non-pharmacological weight loss program.
Trial: NCT02055872
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01052792
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium Tablets 550 mg
Trial: NCT00292942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
Trial: NCT02774460
Drug: Zestril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
Trial: NCT02774460
Drug: Atacand®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
Trial: NCT02774460
Drug: Norvasc®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
Trial: NCT02774460
Drug: Treatment X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
Trial: NCT02774460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
Trial: NCT03613740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will be administered 30 minutes before breakfast.
Trial: NCT00268723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI QID
Trial: NCT00625131
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment placebo transdermal patch
Trial: NCT00771914
Drug: Both Aspirin and Lovaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza 4 grams plus aspirin 81 mg
Trial: NCT02167958
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~.
Trial: NCT03771755
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Trial: NCT03771755
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Trial: NCT01636765
Drug: No Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention.
Trial: NCT01046136
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid 7 days
Trial: NCT01266876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two SC injections in the abdomen only.
Trial: NCT00853112
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet form, single dose (Day 1)
Trial: NCT02058108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
Trial: NCT02561273
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02561273
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02051764
Drug: Florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 megabecquerel (MBq) IV single-dose